Ensysce Biosciences (NASDAQ:ENSC) has witnessed a significant increase in its share price on Friday, following the announcement of a strategic review aimed at enhancing shareholder value.
On Wednesday, the company revealed that its Board of Directors is assessing a variety of strategic alternatives, which may encompass partnerships, licensing agreements, or potential asset sales. This review is part of a broader strategy to support the development of its proprietary technologies, particularly the Trypsin-Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR) platforms.
Lynn Kirkpatrick, CEO of Ensysce Biosciences, stated, “Our technologies were designed to fundamentally improve the safety profile of opioids, and we believe they have relevance well beyond a single class.” Kirkpatrick also noted that the company is carefully considering strategic alternatives that could unlock additional value for shareholders while remaining focused on advancing its TAAP and MPAR platforms.
Ensysce Biosciences is a clinical-stage pharmaceutical company dedicated to developing a new class of safer opioid medications for the treatment of severe pain. By utilising its proprietary TAAP and MPAR technologies, Ensysce aims to create tamper-resistant therapeutic options that mitigate the risks associated with opioid abuse and oral overdose, whilst maintaining robust analgesic efficacy.
At the time of publication, Ensysce Biosciences shares experienced a rise of 58.66%, reaching a price of $0.63, according to data from Benzinga Pro.
For those interested in research funding opportunities in the field of opioid safety and innovation, resources can be found through various governmental and private sector initiatives, which may provide support for related research projects.